Abstract
The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.
Keywords: Tau oligomers, immunotherapy, axonal transport, phosphorylation, neurodegenerative diseases, MTBR, frontotemporal dementia, TFGs, PDC, rTg4510, FTLD-tau, behavioral abnormalities, parkinsonism-dementia
Current Alzheimer Research
Title: Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
Volume: 8 Issue: 6
Author(s): C. A. Lasagna-Reeves, D. L. Castillo-Carranza, G. R. Jackson and R. Kayed
Affiliation:
Keywords: Tau oligomers, immunotherapy, axonal transport, phosphorylation, neurodegenerative diseases, MTBR, frontotemporal dementia, TFGs, PDC, rTg4510, FTLD-tau, behavioral abnormalities, parkinsonism-dementia
Abstract: The aggregation and accumulation of the microtubule-associated protein (Tau) is a pathological hallmark of Alzheimer disease (AD) and many neurodegenerative diseases. For a long time research has focused on neurofibrillary tangles (NFTs) and other large meta-stable inclusions composed of aggregated hyperphosphorylated tau protein. The correlation between these structures and disease progression produced conflicting results; moreover, the mechanism of their formation remains poorly understood. Lately, the significance and toxicity of NFTs have been challenged and a new aggregated tau entity has emerged as the true pathogenic species in tauopathies and a possible mediator of Aβ toxicity in AD; specifically, aggregates of a size intermediate between monomers and NFTs the so-called tau oligomers. Tremendous efforts have been devoted toward the optimization of a safe vaccine for AD by targeting Aβ peptide; despite the disappointing results, these studies produced a wealth of useful knowledge, which should be considered in developing taubased immunotherapy. Herein, we discuss the evidence supporting the critical role of tau oligomers in AD, the potential and challenges for targeting them by immunotherapy as a novel approach for AD treatment.
Export Options
About this article
Cite this article as:
A. Lasagna-Reeves C., L. Castillo-Carranza D., R. Jackson G. and Kayed R., Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717177
DOI https://dx.doi.org/10.2174/156720511796717177 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
CNS & Neurological Disorders - Drug Targets Targeted Blood-to-Brain Drug Delivery – 10 Key Development Criteria
Current Pharmaceutical Biotechnology Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine Vascular Patency: A Biomarker and Clinical Target Quantified with High Resolution MRI and Novel Cellular Pathways
Current Neurovascular Research Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Choline-Containing Phospholipids: Structure-Activity Relationships Versus Therapeutic Applications
Current Medicinal Chemistry Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Inflammatory Systemic Biomarkers in Setting Acute Coronary Syndromes - Effects of the Diurnal Variation
Current Drug Targets A Synopsis on the Role of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Marking the Centennial of Alzheimers First Report of the Disease with a Perspective of Ongoing Research and Future Challenge
Current Alzheimer Research Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Meet Our Associate Editor
Current Alzheimer Research An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Optimized Turmeric Extract Reduces β-Amyloid and Phosphorylated Tau Protein Burden in Alzheimer’s Transgenic Mice
Current Alzheimer Research Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology The Implications of Autophagy in Alzheimer’s Disease
Current Alzheimer Research 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry